secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-05-14T12:15:14+00:00
Accession:  0001193125-26-222890
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus appoints Brent Pfeiffenberger to board; shareholders approve 3M share increase for equity plan
--------------------------------------------------------------------------------

- Appointed Brent Pfeiffenberger (CEO Century Therapeutics, former SVP BMS) to board, expanding to 7 members.
- Stockholders approved amendment to 2024 Equity Plan increasing authorized shares by 3M to total 5M shares.
- All six director nominees elected; advisory say-on-pay approved with 92% of votes cast in favor.
- CRB-701 Nectin-4 ADC data at ASCO 2026; FDA alignment on registration path for HNSCC; registrational study this summer.
- CANYON-1 Phase 1b study for CRB-913 (CB1 inverse agonist) on track to complete summer 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526222890/0001193125-26-222890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526222890/crbp-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-222890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer